Company / Shareholders' Equity
Taysha Gene Therapies, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$246.9M
FY2025
5-year range
$949.0K / $246.9M
FY2021-FY2025
Trend
+229.5%
vs FY2024
Sector context
#147 of 213
Health Care
What the data says
Shareholders' Equity changed +230% YoY in FY2025, a notable deviation from the 5-year average annual change of +1573%.
Based on SEC 10-K filings.
$247M in FY2025 with a 5-year CAGR of -0.3%.
Improved from $949,000 to $247M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +37.3%
- 5-Year CAGR
- -0.3%
- 10-Year CAGR
- -
Sector benchmark
#147 of 213 in Health CareTop 69% of 213This company $246.9M Sector average $2.5B
▼
-90.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.3%, indicating a declining trend.
- In FY2025, shareholders' equity increased 229.5% year-over-year.
- Ranks #147 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $246.9M | +229.5% |
| FY2024 | $74.9M | +7796.4% |
| FY2023 | $949.0K | -99.0% |
| FY2022 | $95.4M | +0.0% |
| FY2021 | $95.4M | -62.0% |
| FY2020 | $251.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026